Compare stocks

Formycon AG is a biotechnology company based in Planegg, Germany, specializing in the development of biosimilar products. The company focuses primarily on creating biosimilar versions of top-selling biopharmaceuticals, addressing fields such as ophthalmology and immunology. Known for its significant expertise in protein and biopharmaceutical development, Formycon leverages its proprietary technical platform to advance its biosimilar pipeline. The company's strategic positioning includes partnerships with other pharmaceutical firms to co-develop and commercialize its biosimilar candidates. Formycon's competitive strength lies in its robust development capabilities and focus on high-growth therapeutic areas.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.